WCI

Login Sign Up Sitemap
Home > RI Related News > RI Related News

RI Related News

게시글 목록
No TItle Name Date Hit
725 Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients WCI Secretariat 2022/06/02 2188
724 Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer WCI Secretariat 2022/06/02 2174
723 Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes WCI Secretariat 2022/06/02 2294
722 Facility for Rare Isotope Beams opens its doors to Discovery WCI Secretariat 2022/06/02 2266
721 Laurentis is Helping Meet Global Demands by Increasing He-3 Production WCI Secretariat 2022/06/02 2180
720 CNNC Begins Production of carbon-14 at Qinshan reactor WCI Secretariat 2022/06/02 2246
719 QSAM Biosciences Doses First Patient in its Clinical Trial for Cyclosam®, Radiopharmaceutical Drug Candidate for the Treatment of Bone Cancer WCI Secretariat 2022/06/02 2138
718 POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program WCI Secretariat 2022/06/02 2167
717 First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial WCI Secretariat 2022/06/02 2133
716 QSAM Biosciences Receives Japanese Patent for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam® WCI Secretariat 2022/05/04 2268
715 Blue Earth Therapeutics Announces U.S. FDA Clearance for Investigational New Drug (IND) Application for 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer WCI Secretariat 2022/05/04 2184
714 First African Association of Radiopharmacy Created to Help Improve Diagnosis and Treatment of Diseases WCI Secretariat 2022/05/04 2239
713 POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting WCI Secretariat 2022/05/04 2326
712 ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177 WCI Secretariat 2022/05/04 2225
711 ITM Announces Successful Completion of Patient Recruitment for its Phase III Trial, COMPETE, with Lead Radiotherapeutic ITM-11 (n.c.a. lutetium-177-edotreotide) WCI Secretariat 2022/05/04 2326
First Prev 1 2 3 4 5 6 7 8 9 10 End (55 Page)

비밀글입니다!

글작성시 입력했던 비밀번호를 입력해주세요.